Standard Biotools Stock Volume Indicators Chaikin AD Line
| LAB Stock | USD 0.97 -0.02 -2.02% |
| Symbol |
Indicator |
The output start index for this execution was zero with a total number of output elements of sixty-one. The Accumulation/Distribution line was developed by Marc Chaikin. It is interpreted by looking at a divergence in the direction of the indicator relative to Standard Biotools price. If the Accumulation/Distribution Line is trending upward it indicates that the price may follow. If the Accumulation/Distribution Line becomes flat while Standard Biotools price is still rising (or falling) then it signals a flattening of the price values.
Standard Biotools Technical Analysis Modules
Most technical analysis of Standard Biotools help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Standard from various momentum indicators to cycle indicators. When you analyze Standard charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Standard Biotools Inc
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people. The stock overview for Standard Biotools summarizes business drivers, financial profile, and market behavior. The company is positioned within Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 0.89, profit margin of -87.77%. Standard Biotools has market cap of 380.68 M, ROE of -13.13%.
Methodology
Unless otherwise specified, financial data for Standard Biotools is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Standard (USA Stocks:LAB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Standard Biotools may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Learn to be your own money manager
Tracking Standard Biotools inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Standard Biotools pair trading
Pair trading with Standard Biotools can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Standard Biotools Pair Trading
Standard Biotools Pair Trading Analysis
The ability to find closely correlated positions to Standard Biotools could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Standard Biotools when you sell it.
The correlation of Standard Biotools is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.
Correlation analysis and pair trading evaluation for Standard Biotools can be used to frame hedging context. The approach can be applied within sectors or across broader universes.More Resources for Standard Stock Analysis
A structured review of Standard Biotools often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Standard Biotools Stock. Outlined below are key reports that provide context for Standard Biotools Stock:Standard Biotools has market cap of 380.68 M, operating margin of -29.42%, ROE of -13.13%. Use Correlation Analysis to explore allocation context. This includes a position in Standard Biotools within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.Analysis related to Standard Biotools should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Earnings Share -0.15 | Revenue Per Share | Quarterly Revenue Growth -0.14 | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than book value, which reflects Standard accounting equity. Standard Biotools' market capitalization is 380.68 M. A P/B ratio of 0.89 suggests Standard Biotools trades near or below book value. Enterprise value stands at 222.36 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Standard Biotools' intrinsic value and market price are different measures derived from different inputs. For Standard Biotools, key inputs include a P/B ratio of 0.89, a profit margin of -87.77%, ROE of -13.13%, and revenue of 85.33 M. By contrast, market price reflects the level where buyers and sellers transact.